Bulletin "Veterinary biotechnology"

Veterynarna biotehnologija – Veterinary biotechnology, 2018, 32(1), 459-465 [in Ukrainian]. https://doi.org/10.31073/vet_biotech32(1)-62

ZADOROZHNA V.e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.VYNNYK N., e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

SI "The L.V. Gromoshevsky institute of epidemiology and infectious disease of NAMS of Ukraine"


Introduction. The constant search and expansion of the spectrum of infectious diseases against which vaccines are created, the development of innovative technologies for vaccine procurement, the widespread use of immunization among healthy individuals, in particular as obligatory vaccinations, direct or indirect impact of massive immunization measures on the country's biosafety and other needs to be addressed by a number of bioethical and biosecurity problems.

The purpose of the work is to analyze some issues of bioethics and biosecurity related to the production and use of vaccines for the prevention of human infectious diseases.

Materials and methods of research. The article identified and analyzed the main issues of bioethics and biosecurity associated with the production and use of vaccines for the prevention of human infectious diseases. The issues of bioethics and biosecurity related to the use of unlicensed vaccines in emergency epidemic conditions (on the example of the epidemic of Ebola disease) are discussed; with the need to improve the technology of obtaining seasonal and pandemic influenza vaccines (the use of transplant cell cultures and other technologies instead of chicken embryos, especially concerning the virus A (H3N2)), strengthening measures to prevent unpredictable events after vaccination, etc. Emphasizes the role of vaccination as one of the most significant medical achievements of mankind.

Conclusions and perspectives off other research. In the problem of vaccination, it is always necessary to take into account the fact that the vaccine is administered in a healthy way, and unlike the therapeutic drug, it does not allow us to trace the dynamics of health improvement. At the level of an ordinary member of society, it often complicates awareness of the benefit / risk ratio of vaccination. Vaccine prevention as an object should combine simultaneously the medical, bioethical principles and principles of biosafety, aimed at both society in general and each individual. Its widespread use requires constant, serious scientific support and high moral, social and economic responsibility at all levels – from scientific research, implementation to production, health care to the implementation of immune prevention programs at the state level.

Keywords: vaccine prophylaxis, bioethics, biosecurity, technological process, infectious diseases.


  1. Jeong, H. & Seong, B.L. (2017). Exploiting virus-like particles as innovative vaccines against emerging viral infections. J. Microbiol, 55(3), 220–230.
  2. Kindsmüller, K. & Wagner, R. (2012). Synthetic biology: Impact on the design of innovative vaccines. Human Vaccines, 7(6), 658–662.
  3. Zadorozhna, V.I., Frolov, A.F. & Moiseeva, G.V. (2011). Pytannia bioetyky v problemi imunoprofilaktyky [Questions of bioethics in the problem of immune prophylaxis]. Integratyvna antropologija (mizhnarodnyj medyko-filosofs'kyj zhurnal) – Integrative Anthropology (International Medical and Philosophical Journal), 17(1), 43–46. [in Ukranian].
  4. Zadorozhna, V.I. (2017). Bioeticheskiye aspekty biobezopasnosti, kasayushchiyesya shirokomasshtabnoy spetsificheskoy profilaktiki infektsionnykh bolezney [Bioethical aspects of biosafety, concerning large-scale specific prevention of infectious diseases]. Materialy naukovo-praktychnoi konferencii z mizhnarodnoju uchastju: Infekcijni hvoroby suchasnosti: etiologia, epidemiologia, diagnostyka, likuvannia, profilaktyka, biologichna bezpeka – Materials of the scientific-practical conference with international participation: Infectious diseases of the present: etiology, epidemiology, diagnostics, treatment, prevention, biological safety. (pp. 75–76). Kiev. [in Russian].
  5. WHO: Ethical considerations for use of unregistered interventions for Ebola virus disease (EVD): Summary of the panel discussion. (2014). www.who.int. Retrieved from: http://www.who.int/mediacentre/news/statements/2014/ebola-ethical-review-summary/en/.
  6. WHO: Essential medicines and health products: Vaccines. www.who.int. Retrieved from http://www.who.int/medicines/ebola-treatment/emp_ebola_vaccines/en/.
  7. Milián, E. & Kamen, A.A. (2015). Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines. BioMed Research International, 2015, 11.
  8. Skowronski, D.M., Janjua, N.Z., De Serres, G., Sabaiduc, S., Eshaghi, A., Dickinson, J.A., Fonseca, K. et al. (2014). Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One, 2014. 9(3):e92153.
  9. Wu, N.C., Zost, S.J., Thompson, A.J., Oyen, D., Nycholat, C.M., McBride, R. et al. (2017). A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. www.ncbi.nlm.nih.gov. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667890/.
  10. Raymond, D.D., Stewart, S.M., Lee, J., Ferdman, J., Bajic, G., Do, K.T. et al. (2016). Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nature Medicine, 22, 12, 1465–1469.
  11. Ahmed, S.S., Schur, P.H., MacDonald, N.E. & Steinman, L. (2014). Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. Journal of Autoimmunity, 50, 1–11.
  12. Ahmed, S.S., Montomoli, E., Pasini, F.L. & Steinman, L. (2016). The Safety of Adjuvanted Vaccines Revisited: Vaccine-Induced Narcolepsy. The Israel Medical Association Journal, 18, 216–220.
  13. Ahmed, S.S. & Steinman, L. (2017). Narcolepsy and influenza vaccination-induced autoimmunity. Annals of Translational Medicine, 5, 1, 25.
  14. CDC: Historical Vaccine Safety Concerns (n.d.). www.cdc.gov. Retrieved from https://www.cdc.gov/ vaccinesafety/concerns/concerns-history.html. [in English].
  15. Curtis, T. (2004). Monkeys, viruses, and vaccines. The Lancet, 364, 9432, 407–408.
  16. Han, H.H., Karkada, N., Jayadeva, G. & Dubin, G. (2017). Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysis. Hum. Vaccin. Immunother, 13, 1, 237–244.
  17. Mijatovic-Rustempasic, S., Immergluck, L.C., Parker, T.C. et al. (2017). Shedding of porcine circovirus type 1 DNA and rotavirus RNA by infants vaccinated with Rotarix. J. Human Vaccines & Immunotherapeutics, 13, 4, 928–935.

Download full text in PDF